



# SAFETY DATA SHEET

Revision date 17-Jun-2025

Version 4

Page 1 / 14

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Vecuronium Bromide for Injection (Hospira Inc)  
**Product Code(s)** PZ03166  
**Trade Name:** Not applicable  
**Chemical Family:** Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product used for skeletal muscle relaxation

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: This substance is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

#### OSHA Classification

##### Hazards not otherwise classified (HNOC)

Not applicable

##### Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

### 2.2. Label elements

**Signal word** Not classified

**Hazard statements** Not classified in accordance with international standards for workplace safety.

### 2.3. Other hazards

**Other hazards** An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 2 / 14  
Version 4

## PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

## Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

## Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

#### Hazardous

| Chemical name                          | Weight-% | REACH registration number | EC No (EU Index No)      | Classification according to Regulation (EC) No. 1272/2008 [CLP] | Specific concentration limit (SCL)                                                                               | M-Factor          | M-Factor (long-term) |
|----------------------------------------|----------|---------------------------|--------------------------|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------|----------------------|
| Citric acid (CAS #: 77-92-9)           | *        |                           | 201-069-1 (607-750-00-3) | Eye Irrit. 2A (H319)SE 3 (H335)                                 | Not classified                                                                                                   | No data available | No data available    |
| Vecuronium bromide (CAS #: 50700-72-6) | 1 - 5    |                           | 256-723-9                | Acute Tox. 4 (H302)                                             | Not classified                                                                                                   | No data available | No data available    |
| Sodium hydroxide (CAS #: 1310-73-2)    | **       | -                         | 215-185-5 (011-002-00-6) | Skin Corr. 1A (H314)                                            | Eye Irrit. 2 :: 0.5%<=C<2%<br>Skin Corr. 1A :: C>=5%<br>Skin Corr. 1B :: 2%<=C<5%<br>Skin Irrit. 2 :: 0.5%<=C<2% | No data available | No data available    |
| + Phosphoric acid (CAS #: 7664-38-2)   | **       |                           | 231-633-2 (015-011-00-6) | Skin Corr. 1B (H314)                                            | Eye Irrit. 2 :: 10%<=C<25%<br>Skin Corr. 1B :: C>=25%<br>Skin Irrit. 2 :: 10%<=C<25%                             | No data available | No data available    |

#### NonHazardous

| Chemical name             | Weight-% | REACH registration number | EC No (EU Index No) | Classification according to Regulation (EC) No. 1272/2008 [CLP] | Specific concentration limit (SCL) | M-Factor          | M-Factor (long-term) |
|---------------------------|----------|---------------------------|---------------------|-----------------------------------------------------------------|------------------------------------|-------------------|----------------------|
| Water (CAS #: 7732-18-5)  | *        | -                         | 231-791-2           | Not classified                                                  | Not classified                     | No data available | No data available    |
| Mannitol (CAS #: 69-65-8) | *        | -                         | 200-711-8           | Not classified                                                  | Not classified                     | No data available | No data available    |

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 3 / 14  
Version 4

|                                                 |   |  |           |                |                |                   |                   |
|-------------------------------------------------|---|--|-----------|----------------|----------------|-------------------|-------------------|
| Sodium phosphate, dibasic<br>(CAS #: 7558-79-4) | * |  | 231-448-7 | Not classified | Not classified | No data available | No data available |
|-------------------------------------------------|---|--|-----------|----------------|----------------|-------------------|-------------------|

**Full text of H- and EUH-phrases: see section 16**

**Acute Toxicity Estimate** No information available

| Chemical name                          | Oral LD50 mg/kg | Dermal LD50 mg/kg | Inhalation LC50 - 4 hour - dust/mist - mg/L | Inhalation LC50 - 4 hour - vapor - mg/L | Inhalation LC50 - 4 hour - gas - ppm |
|----------------------------------------|-----------------|-------------------|---------------------------------------------|-----------------------------------------|--------------------------------------|
| Water<br>7732-18-5                     | 89838.9         | No data available | No data available                           | No data available                       | No data available                    |
| Mannitol<br>69-65-8                    | 13500           | No data available | No data available                           | No data available                       | No data available                    |
| Sodium phosphate, dibasic<br>7558-79-4 | 17000           | No data available | No data available                           | No data available                       | No data available                    |
| Citric acid<br>77-92-9                 | 5400            | >2000             | No data available                           | No data available                       | No data available                    |
| Vecuronium bromide<br>50700-72-6       | 455             | No data available | No data available                           | No data available                       | No data available                    |
| Sodium hydroxide<br>1310-73-2          | 325             | 1350              | No data available                           | No data available                       | No data available                    |
| + Phosphoric acid<br>7664-38-2         | 1530            | 2740              | 0.9615                                      | No data available                       | No data available                    |

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

\* Proprietary

\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

|                     |                                                                                                                                                                                    |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Inhalation</b>   | Remove to fresh air. Seek immediate medical attention/advice.                                                                                                                      |
| <b>Eye contact</b>  | Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.                                                               |
| <b>Skin contact</b> | Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.                                                                            |
| <b>Ingestion</b>    | Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. |

### 4.2. Most important symptoms and effects, both acute and delayed

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 4 / 14  
Version 4

**Most important symptoms and effects** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

## **4.3. Indication of any immediate medical attention and special treatment needed**

**Note to physicians** None.

## **Section 5: FIRE-FIGHTING MEASURES**

### **5.1. Extinguishing media**

**Suitable Extinguishing Media** Dry chemical, CO2, alcohol-resistant foam or water spray.

### **5.2. Special hazards arising from the substance or mixture**

**Specific hazards arising from the chemical** Fine particles (such as mists) may fuel fires/explosions.

**Hazardous combustion products** Formation of toxic gases is possible during heating or fire.

#### **Explosion data**

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### **5.3. Advice for firefighters**

**Special protective equipment and precautions for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## **Section 6: ACCIDENTAL RELEASE MEASURES**

### **6.1. Personal precautions, protective equipment and emergency procedures**

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

### **6.2. Environmental precautions**

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### **6.3. Methods and material for containment and cleaning up**

**Methods for containment** Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up** Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated surface thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### **6.4. Reference to other sections**

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## **Section 7: HANDLING AND STORAGE**

### **7.1. Precautions for safe handling**

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 5 / 14  
Version 4

## Advice on safe handling

Minimize dust generation and accumulation. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

## General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

## 7.2. Conditions for safe storage, including any incompatibilities

### Storage Conditions

Store as directed by product packaging.

## 7.3. Specific end use(s)

### Specific use(s)

Pharmaceutical product used for. skeletal muscle relaxation.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### Vecuronium bromide

Pfizer OEL TWA-8 Hr: 60 µg/m<sup>3</sup>

#### Mannitol

Russia

MAC: 10 mg/m<sup>3</sup>

#### Sodium phosphate, dibasic

Russia

MAC: 10 mg/m<sup>3</sup>

#### Citric acid

Czech Republic

4 mg/m<sup>3</sup>

Germany DFG

TWA-MAK: 2 mg/m<sup>3</sup>; I(2);inhalable fraction

Peak: 4 mg/m<sup>3</sup>; respirable fraction

Germany TRGS

TWA-AGW; 2 mg/m<sup>3</sup> (exposure factor 2); inhalable fraction

Russia

MAC: 1 mg/m<sup>3</sup>

Switzerland

TWA-MAK: 2 mg/m<sup>3</sup>; inhalable dust

STEL-KZGW: 4 mg/m<sup>3</sup>; inhalable dust

#### Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m<sup>3</sup>

ACGIH TLV

Ceiling: 2 mg/m<sup>3</sup>

Austria

TWA-TMW: 2 mg/m<sup>3</sup>; inhalable fraction

STEL-KZGW: 4 mg/m<sup>3</sup> (8 X 5 min); inhalable fraction

Bulgaria

TWA: 2.0 mg/m<sup>3</sup>; alkaline aerosols

Czech Republic

1 mg/m<sup>3</sup>

Ceiling: 2 mg/m<sup>3</sup>

Denmark

Ceiling: 2 mg/m<sup>3</sup>;

Estonia

TWA: 1 mg/m<sup>3</sup>;

STEL: 2 mg/m<sup>3</sup>;

Finland

Ceiling: 2 mg/m<sup>3</sup>;

France

2 mg/m<sup>3</sup>

Hungary

TWA-AK: 1 mg/m<sup>3</sup>;

STEL-CK: 2 mg/m<sup>3</sup>;

Ireland

STEL: 2 mg/m<sup>3</sup>;

Ceiling Limit Value

2 mg/m<sup>3</sup>

Latvia

TWA: 0.5 mg/m<sup>3</sup>;

Poland

TWA-NDS: 0.5 mg/m<sup>3</sup>;

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 6 / 14  
Version 4

|                          |                                                                                                          |
|--------------------------|----------------------------------------------------------------------------------------------------------|
| Romania                  | STEL-NDSch: 1 mg/m <sup>3</sup> ;<br>TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 3 mg/m <sup>3</sup> ;           |
| Slovakia                 | TWA: 2 mg/m <sup>3</sup> ;                                                                               |
| Spain                    | STEL (VLA-EC): 2 mg/m <sup>3</sup> ;                                                                     |
| Switzerland              | TWA-MAK: 2 mg/m <sup>3</sup> ; inhalable dust<br>STEL-KZGW: 2 mg/m <sup>3</sup> ; inhalable dust         |
| OSHA PEL                 | TWA: 2 mg/m <sup>3</sup><br>(vacated) Ceiling: 2 mg/m <sup>3</sup><br>STEL: 2 mg/m <sup>3</sup> ;        |
| United Kingdom           |                                                                                                          |
| <b>+ Phosphoric acid</b> |                                                                                                          |
| ACGIH TLV                | TWA: 1 mg/m <sup>3</sup><br>STEL: 3 mg/m <sup>3</sup>                                                    |
| Austria                  | TWA-TMW: 1 mg/m <sup>3</sup> ;<br>STEL-KZGW: 2 mg/m <sup>3</sup> (4 X 15 min);                           |
| Bulgaria                 | TWA: 1.0 mg/m <sup>3</sup> ;<br>STEL: 2.0 mg/m <sup>3</sup> ;                                            |
| Czech Republic           | 1 mg/m <sup>3</sup><br>Ceiling: 2 mg/m <sup>3</sup>                                                      |
| Denmark                  | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |
| Estonia                  | TWA: 1 mg/m <sup>3</sup> ; vapor<br>STEL: 2 mg/m <sup>3</sup> ; vapor                                    |
| European Union           | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |
| Finland                  | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |
| France                   | 1 mg/m <sup>3</sup>                                                                                      |
| Germany DFG              | TWA-MAK: 2 mg/m <sup>3</sup> ; I(2);inhalable fraction<br>Peak: 4 mg/m <sup>3</sup> ; inhalable fraction |
| Germany TRGS             | TWA-AGW: 2 mg/m <sup>3</sup> (exposure factor 2); inhalable fraction                                     |
| Hungary                  | TWA-AK: 1 mg/m <sup>3</sup> ;<br>STEL-CK: 2 mg/m <sup>3</sup> ;                                          |
| Ireland                  | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |
| Italy MDLPS              | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |
| Latvia                   | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |
| Netherlands              | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |
| Poland                   | TWA-NDS: 1 mg/m <sup>3</sup> ;<br>STEL-NDSch: 2 mg/m <sup>3</sup> ;                                      |
| Romania                  | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |
| Slovakia                 | TWA: 1 mg/m <sup>3</sup> ;<br>Ceiling: 2 mg/m <sup>3</sup> ;                                             |
| Spain                    | TWA-(VLA-ED): 1 mg/m <sup>3</sup> ;<br>STEL (VLA-EC): 2 mg/m <sup>3</sup> ;                              |
| Switzerland              | TWA-MAK: 2 mg/m <sup>3</sup> ; inhalable dust<br>STEL-KZGW: 4 mg/m <sup>3</sup> ; inhalable dust         |
| OSHA PEL                 | TWA: 1 mg/m <sup>3</sup><br>(vacated) TWA: 1 mg/m <sup>3</sup><br>(vacated) STEL: 3 mg/m <sup>3</sup>    |
| United Kingdom           | TWA: 1 mg/m <sup>3</sup> ;<br>STEL: 2 mg/m <sup>3</sup> ;                                                |

**Pfizer Occupational Exposure Band**

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 7 / 14  
Version 4

## (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

### Thermal hazards

No information available.

### Environmental exposure controls

No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

#### Physical state

Powder

#### Color

White to off-white

#### Odor

No information available.

#### Odor threshold

No information available

#### Property

#### Values

#### Melting point / freezing point

No data available

#### Boiling point or initial boiling point and boiling range

No data available

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 8 / 14  
Version 4

|                                                    |                          |
|----------------------------------------------------|--------------------------|
| Flammability (solid, gas)                          | No data available        |
| Lower and upper explosion limit/flammability limit |                          |
| Lower explosion limit                              | No data available        |
| Upper explosion limit                              | No data available        |
| Flash point                                        | No data available        |
| Autoignition temperature                           | No data available        |
| Decomposition temperature                          |                          |
| SADT (°C)                                          | No data available        |
| pH                                                 | No data available        |
| pH (as aqueous solution)                           | No data available        |
| Kinematic viscosity                                | No data available        |
| Dynamic viscosity                                  | No data available        |
| Solubility                                         | No data available        |
| Vapor pressure                                     | No data available        |
| Density and/or relative density                    | No data available        |
| Bulk density                                       | No data available        |
| Liquid Density                                     | No data available        |
| Vapor density                                      | No data available        |
| Particle characteristics                           |                          |
| Particle Size                                      | No information available |
| Particle Size Distribution                         | No information available |

## 9.2. Other information

|                   |         |
|-------------------|---------|
| Molecular formula | Mixture |
| Molecular weight  | Mixture |

### 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

## Section 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

|            |                           |
|------------|---------------------------|
| Reactivity | No information available. |
|------------|---------------------------|

### 10.2. Chemical stability

|           |                                 |
|-----------|---------------------------------|
| Stability | Stable under normal conditions. |
|-----------|---------------------------------|

### Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

### 10.3. Possibility of hazardous reactions

|                                    |                           |
|------------------------------------|---------------------------|
| Possibility of hazardous reactions | No information available. |
|------------------------------------|---------------------------|

### 10.4. Conditions to avoid

|                     |                                                                    |
|---------------------|--------------------------------------------------------------------|
| Conditions to avoid | Fine particles (such as dust and mists) may fuel fires/explosions. |
|---------------------|--------------------------------------------------------------------|

### 10.5. Incompatible materials

|                        |                                                              |
|------------------------|--------------------------------------------------------------|
| Incompatible materials | As a precautionary measure, keep away from strong oxidizers. |
|------------------------|--------------------------------------------------------------|

### 10.6. Hazardous decomposition products

|                                  |                    |
|----------------------------------|--------------------|
| Hazardous decomposition products | No data available. |
|----------------------------------|--------------------|

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008



# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 9 / 14  
Version 4

|                                          |                                                                                                        |
|------------------------------------------|--------------------------------------------------------------------------------------------------------|
| <b>General Information:</b>              | The information included in this section describes the potential hazards of the individual ingredients |
| <b>Short term</b>                        | Active ingredient may be harmful if swallowed.                                                         |
| <b>Long Term:</b>                        | Repeated or prolonged exposure may cause effects similar to those seen in clinical use.                |
| <b>Known Clinical Effects:</b>           | Drugs of this class may cause muscle weakness, respiratory depression.                                 |
| <b>Acute toxicity</b>                    | Based on available data, the classification criteria are not met.                                      |
| <b>Serious eye damage/eye irritation</b> | Based on available data, the classification criteria are not met.                                      |
| <b>Skin corrosion/irritation</b>         | Based on available data, the classification criteria are not met.                                      |
| <b>Respiratory or skin sensitization</b> | Based on available data, the classification criteria are not met.                                      |
| <b>STOT - single exposure</b>            | Based on available data, the classification criteria are not met.                                      |
| <b>STOT - repeated exposure</b>          | Based on available data, the classification criteria are not met.                                      |
| <b>Reproductive toxicity</b>             | Based on available data, the classification criteria are not met.                                      |
| <b>Germ cell mutagenicity</b>            | Based on available data, the classification criteria are not met.                                      |
| <b>Carcinogenicity</b>                   | Based on available data, the classification criteria are not met.                                      |
| <b>Aspiration hazard</b>                 | Based on available data, the classification criteria are not met.                                      |

## **Acute Toxicity: (Species, Route, End Point, Dose)**

### **Mannitol**

Rat Oral LD 50 13500 mg/kg  
Mouse Oral LD 50 22 g/kg

### **Citric acid**

Mouse Oral LD50 5400 mg/kg

### **Vecuronium bromide**

Rat Oral LD50 455 mg/kg  
Mouse Oral LD 50 41 mg/kg  
Rat Intravenous LD 50 0.20 mg/kg  
Mouse Intravenous LD 50 0.05 mg/kg

### **Sodium hydroxide**

Mouse IP LD50 40 mg/kg

### **+ Phosphoric acid**

Rat Oral LD50 1530 mg/kg  
Rabbit Dermal LD 50 2730 mg/kg

| Chemical name             | Oral LD50             | Dermal LD50             | Inhalation LC50                      |
|---------------------------|-----------------------|-------------------------|--------------------------------------|
| Water                     | > 90 mL/kg ( Rat )    | -                       | -                                    |
| Mannitol                  | = 13500 mg/kg ( Rat ) | -                       | -                                    |
| Sodium phosphate, dibasic | = 17 g/kg ( Rat )     | -                       | -                                    |
| Citric acid               | = 3 g/kg ( Rat )      | > 2000 mg/kg ( Rat )    | -                                    |
| Vecuronium bromide        | = 455 mg/kg ( Rat )   | -                       | -                                    |
| Sodium hydroxide          | = 325 mg/kg ( Rat )   | = 1350 mg/kg ( Rabbit ) | -                                    |
| + Phosphoric acid         | = 1530 mg/kg ( Rat )  | = 2740 mg/kg ( Rabbit ) | = 3846 mg/m <sup>3</sup> ( Rat ) 1 h |

## **Irritation / Sensitization: (Study Type, Species, Severity)**

### **Citric acid**

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Mild

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 10 / 14  
Version 4

## Sodium hydroxide

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Severe

## + Phosphoric acid

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Severe

## **Carcinogenicity**

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 11.2.2. Other information

**Other adverse effects** No information available.

## **Section 12: ECOLOGICAL INFORMATION**

### **Environmental Overview:**

Environmental properties have not been investigated. Releases to the environment should be avoided.

### 12.1. Toxicity

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

##### + Phosphoric acid

*Gambusia affinis* (Mosquitofish) LC50 96 hours 3-3.5 mg/L  
*Daphnia magna* (Water Flea) EC-50 12 4.6 mg/L

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment** Based on available data, the classification criteria are not met.

| Chemical name | PBT and vPvB assessment |
|---------------|-------------------------|
|---------------|-------------------------|

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 11 / 14  
Version 4

|                           |                                            |
|---------------------------|--------------------------------------------|
| Sodium phosphate, dibasic | PBT assessment does not apply              |
| Citric acid               | Not PBT/vPvB                               |
| Sodium hydroxide          | Not PBT/vPvB PBT assessment does not apply |
| + Phosphoric acid         | Not PBT/vPvB PBT assessment does not apply |

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

## 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

#### Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

|                                    |                |
|------------------------------------|----------------|
| <b>UN number:</b>                  | Not applicable |
| <b>UN proper shipping name:</b>    | Not applicable |
| <b>Transport hazard class(es):</b> | Not applicable |
| <b>Packing group:</b>              | Not applicable |
| <b>Environmental Hazard(s):</b>    | Not applicable |

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

|                                             |            |
|---------------------------------------------|------------|
| <b>CERCLA/SARA Section 313 de minimus %</b> | Not Listed |
| <b>California Proposition 65</b>            | Not Listed |
| <b>TSCA</b>                                 | Present    |
| <b>EINECS</b>                               | 231-791-2  |
| <b>AICS</b>                                 | Present    |

Mannitol

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 12 / 14  
Version 4

|                                                                         |                          |
|-------------------------------------------------------------------------|--------------------------|
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed               |
| <b>California Proposition 65</b>                                        | Not Listed               |
| <b>TSCA</b>                                                             | Present                  |
| <b>EINECS</b>                                                           | 200-711-8                |
| <b>AICS</b>                                                             | Present                  |
| Sodium phosphate, dibasic                                               |                          |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed               |
| <b>Hazardous Substances RQs</b>                                         | 5000 lb                  |
| <b>California Proposition 65</b>                                        | Not Listed               |
| <b>TSCA</b>                                                             | Present                  |
| <b>EINECS</b>                                                           | 231-448-7                |
| <b>AICS</b>                                                             | Present                  |
| <b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b> | Schedule 5<br>Schedule 6 |
| Citric acid                                                             |                          |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed               |
| <b>California Proposition 65</b>                                        | Not Listed               |
| <b>TSCA</b>                                                             | Present                  |
| <b>EINECS</b>                                                           | 201-069-1                |
| <b>AICS</b>                                                             | Present                  |
| Vecuronium bromide                                                      |                          |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed               |
| <b>California Proposition 65</b>                                        | Not Listed               |
| <b>EINECS</b>                                                           | 256-723-9                |
| <b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b> | Schedule 4               |
| Sodium hydroxide                                                        |                          |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed               |
| <b>Hazardous Substances RQs</b>                                         | 1000 lb                  |
| <b>California Proposition 65</b>                                        | Not Listed               |
| <b>TSCA</b>                                                             | Present                  |
| <b>EINECS</b>                                                           | 215-185-5                |
| <b>AICS</b>                                                             | Present                  |
| <b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b> | Schedule 5<br>Schedule 6 |
| + Phosphoric acid                                                       |                          |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed               |
| <b>Hazardous Substances RQs</b>                                         | 5000 lb                  |
| <b>California Proposition 65</b>                                        | Not Listed               |
| <b>TSCA</b>                                                             | Present                  |
| <b>EINECS</b>                                                           | 231-633-2                |
| <b>AICS</b>                                                             | Present                  |
| <b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b> | Schedule 5<br>Schedule 6 |

## National regulations

### Germany

**Chemical Prohibition Ordinance (ChemVerbotsV)**

Not applicable

| Chemical name                    | Number | Class    |
|----------------------------------|--------|----------|
| Vecuronium bromide<br>50700-72-6 | 5.2.4  | Class II |

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 13 / 14  
Version 4

TRGS 905

Not applicable

## Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable

Major Accidents Ordinance SR 814.012 Not applicable

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

| Chemical name                  | Restricted substance per REACH Annex XVII | Substance subject to authorization per REACH Annex XIV |
|--------------------------------|-------------------------------------------|--------------------------------------------------------|
| Citric acid<br>77-92-9         | 75                                        | -                                                      |
| Sodium hydroxide<br>1310-73-2  | 75                                        | -                                                      |
| + Phosphoric acid<br>7664-38-2 | 75                                        | -                                                      |

## Persistent Organic Pollutants

Not applicable

## Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

| Chemical name          | Biocidal Products Regulation (EU) No 528/2012 (BPR)                                                                                                            |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Citric acid<br>77-92-9 | Product-type 2: Disinfectants and algacides not intended for direct application to humans or animals Product-type 6: Preservatives for products during storage |

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing Chemicals Inventory

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**NZIoC** - New Zealand Inventory of Chemicals

**TCSI** - Taiwan Chemical Substance Inventory

## 15.2. Chemical safety assessment

# SAFETY DATA SHEET

Product Name Vecuronium Bromide for Injection (Hospira Inc)  
Revision date 17-Jun-2025

Page 14 / 14  
Version 4

## Chemical Safety Report

No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

#### **Full text of any hazard and/or precautionary statements referred to under Sections 2-15**

H302 - Harmful if swallowed H314 - Causes severe skin burns and eye damage H319 - Causes serious eye irritation H335 - May cause respiratory irritation

#### **Data Sources:**

Pfizer proprietary drug development information. Publicly available toxicity information.

#### **Reason for revision**

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

#### **Revision date**

17-Jun-2025

#### **Prepared By**

Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**